Becotatug vedotin shows 20.9% objective response in recurrent head and neck squamous cell carcinoma after prior therapy
For patients with advanced head and neck cancer, a new drug showed a 21% response rate in early testing
This multicenter, Phase IIa trial evaluated intravenous becotatug vedotin in 67 patients with recurrent or metastatic squamous cell carcinom…
A new drug shrank tumors in 21% of patients with advanced head and neck cancer who had run out of standard treatment options.
Phase 1b ABBV-368 combinations in recurrent/metastatic HNSCC show 14.3% overall response rate
Early study of ABBV-368 plus other drugs showed limited tumor response in head and neck cancer patients
This phase 1b, multicenter, open-label study enrolled 30 adults with recurrent or metastatic head and neck squamous cell carcinoma across th…
Early trials of ABBV-368 combined with other drugs showed limited tumor shrinkage in head and neck cancer patients despite a generally safe …
Low OT-NLR predicts superior survival in recurrent/metastatic HNSCC treated with cetuximab plus nivolumab
A Simple Blood Ratio May Predict Cancer Drug Success
This Phase II clinical trial evaluated patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) receiving combine…
A low white blood cell ratio found in blood tests predicts better survival and treatment response for advanced head and neck cancer patients…
Phase 3 trial compares pembrolizumab with or without lenvatinib in PD-L1+ recurrent/metastatic HNSCC
Phase 3 trial tests pembrolizumab with or without lenvatinib for advanced head and neck cancer
A phase 3 randomized controlled trial enrolled 511 patients with PD-L1 selected recurrent or metastatic head and neck squamous cell carcinom…
A completed Phase 3 trial tested pembrolizumab with or without lenvatinib for advanced head and neck cancer, but detailed results are not ye…
Research across Head and Neck Cancer
Related studies from across the Head and Neck Cancer family.
Immunonutrition may improve management of radiation-induced oral mucositis in head and neck cancer patients
Immunonutrition may help manage mouth sores in head and neck cancer
This narrative review examines the role of immunonutrition for managing oral mucositis in patients with head and neck malignancies undergoin…
Patients with head and neck cancer often suffer from painful mouth sores. New evidence suggests immunonutrition could help manage these symp…
Lenvatinib plus pembrolizumab did not improve overall survival compared to standard of care
Trial shows lenvatinib and pembrolizumab do not improve survival
This Phase 2 randomized trial evaluated lenvatinib and pembrolizumab in 374 adults with recurrent or metastatic head and neck squamous cell …
A Phase 2 trial found that a combination of lenvatinib and pembrolizumab did not improve overall survival for patients with advanced head an…
High tumor mutational burden correlates with improved objective response rate in HNSCC patients
High tumor mutation burden predicts better results in head cancer
This meta-analysis of 1472 patients with head and neck squamous cell carcinoma (HNSCC) found that high tumor mutational burden (TMB) is asso…
A high number of mutations in a tumor may help doctors predict which patients will respond best to immunotherapy.
Combination Therapies Improve Progression Free Survival in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Combination therapies show promise for advanced head and neck cancer
This meta-analysis evaluated combination therapies involving targeted agents or immunotherapy with chemotherapy for patients with recurrent …
Combining immunotherapy or targeted drugs with chemotherapy may help patients with advanced head and neck cancer live longer without the dis…
Postoperative radiotherapy reduces local and peristomal recurrence rates in laryngeal cancer patients with preoperative tracheotomy
Radiotherapy May Lower Recurrence Risk After Laryngectomy for Cancer
This meta-analysis of 4339 patients evaluates the impact of postoperative radiotherapy (PORT) on recurrence rates following total laryngecto…
Postoperative radiotherapy may lower the risk of cancer returning in the throat area for patients who had a tracheotomy before surgery.
Zygomatic implants provide high survival rates for maxillary reconstruction in head and neck cancer patients
Zygomatic implants show high survival for head and neck cancer
This systematic review and meta-analysis of 294 patients with extensive maxillary defects found a 97% overall implant survival rate. The ana…
New data shows zygomatic implants have a 97% survival rate, offering a reliable way to restore jaw function after cancer surgery.
Camrelizumab and apatinib show higher response rates and survival in treatment-naive patients with ESCC
Treatment Naive Patients Show Better Survival with Camrelizumab and Apatinib
This meta-analysis evaluates the efficacy of camrelizumab plus apatinib for advanced or metastatic esophageal squamous cell carcinoma. The a…
Patients with advanced esophageal cancer who have not had prior treatment may see better survival rates when using a combination of camreliz…
Sintilimab may trigger autoimmune GFAP astrocytopathy in esophageal squamous cell carcinoma patients
New cancer treatment may cause rare brain inflammation in patients
This case report and literature review describes a patient with advanced esophageal squamous cell carcinoma who developed autoimmune GFAP as…
A new type of immunotherapy for esophageal cancer can trigger a rare brain condition, requiring doctors to watch for early signs of neurolog…
HPV shows strong association with oropharyngeal SCC while other oncogenic viruses show limited evidence
Viruses linked to oral and throat cancers in new review
This systematic review examines the role of various oncogenic viruses in oral and oropharyngeal squamous cell carcinomas. It identifies a co…
A strong link between HPV and throat cancer is confirmed, while other viruses show less clear evidence of causing cancer.
Prophylactic PEG tube placement improves nutritional status and reduces hospitalizations for head and neck cancer patients
Proactive Feeding Tubes May Improve Support for Head and Neck Cancer
This meta-analysis of 1279 patients evaluates prophylactic versus reactive percutaneous endoscopic gastrostomy (PEG) tubes in head and neck …
Early placement of feeding tubes may improve nutritional stability and reduce hospital stays for patients undergoing head and neck cancer tr…
Neoadjuvant chemoimmunotherapy improves pathological response and surgical rates in resectable esophageal squamous cell carcinoma
Immune therapy shows promise for esophageal squamous cell carcinoma
This meta-analysis of randomized controlled trials involving 1070 patients found that neoadjuvant chemoimmunotherapy (NIC) significantly imp…
Adding immune checkpoint inhibitors to chemotherapy before surgery significantly improves tumor response rates in patients with esophageal c…
Hyperspectral imaging shows strong diagnostic performance for oral cancer detection in scoping review
Hyperspectral imaging shows promise for detecting oral cancer
This scoping review of 15 studies found that hyperspectral imaging (HSI) demonstrates strong diagnostic performance for detecting and charac…
A new review finds hyperspectral imaging can spot oral cancer with high accuracy, offering a non-contact alternative for margin assessment.
Questions about Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
What is the objective response rate for becotatug vedotin in recurrent head and neck cancer?
Becotatug vedotin showed a 20.9% objective response rate in recurrent or metastatic head and neck squamous cell carcinoma after prior therapy.
Full answer →